Thomas Spitznagel - 12 Feb 2026 Form 4 Insider Report for MACROGENICS INC (MGNX)

Role: Sr VP, Technical Ops
Signature: /s/ Beth A. Smith, Attorney-in-fact
Issuer symbol: MGNX
Transactions as of: 12 Feb 2026
Net transactions value: -$9,439
Form type: 4
Filing time: 17 Feb 2026, 18:24:23 UTC
Previous filing: 10 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Spitznagel Thomas	Sr VP, Technical Ops	9704 MEDICAL CENTER DRIVE, ROCKVILLE	/s/ Beth A. Smith, Attorney-in-fact	17 Feb 2026	0001675464

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MGNX	Common Stock	Options Exercise		+13,332	+43%		44,063	15 Feb 2026	Direct	F1
transaction	MGNX	Common Stock	Tax liability	$9,439	-5,520	-13%	$1.71	38,543	15 Feb 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MGNX	Restricted Stock Unit	Options Exercise	$0	-13,332	-100%	$0.000000	0	15 Feb 2026	Common Stock	13,332		Direct	F1
transaction	MGNX	Restricted Stock Unit	Award	$0	+25,000		$0.000000	25,000	12 Feb 2026	Common Stock	25,000		Direct	F2
transaction	MGNX	Employee Stock Option (right to buy)	Award	$0	+150,000		$0.000000	150,000	12 Feb 2026	Common Stock	150,000	$1.71	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 15, 2023, the reporting person was granted 40,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis.
F2	Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.
F3	12.5% of the shares underlying the grant became exercisable one year after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.